All News
Filter News
Found 118 articles
-
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
1/13/2020
Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
BioSpace Unveils Its Annual List of Up-and-Coming Life Sciences Companies
1/6/2020
BioSpace, the leader in life sciences news and careers, today announced their NextGen Bio "Class of 2020," a list of 21 up-and-coming life sciences companies in the United States.
-
BioSpace Unveils Its Annual List of Up-and-Coming Life Sciences Companies
1/6/2020
BioSpace, the leader in life sciences news and careers, announced their NextGen Bio "Class of 2020," a list of 21 up-and-coming life sciences companies in the United States.
-
Cyclerion to Present at the J.P. Morgan Healthcare Conference
12/23/2019
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will present at the J.P. Morgan Healthcare Conference on Wednesday,
-
Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition
12/2/2019
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today multiple executive appointments.
-
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
11/27/2019
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced it will present at the Evercore ISI 2nd Annual HealthCONx Conference
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance
10/31/2019
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its third quarter 2019 results and recent business performance. Ironwood also announced that it is increasing its full year 2019 total revenue and adjusted EBITDA from continuing operations guidance.
-
Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.
-
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
10/30/2019
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced topline results from its Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in diabetic nephropathy.
-
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
10/30/2019
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced topline results from its CAPACITY Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in heart failure with preserved ejection fraction (HFpEF).
-
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference
9/3/2019
Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.
-
InSphero human liver disease platform selected to test Cyclerion's sGC stimulator technology as potential therapeutic approach for NASH and fibrosis
8/27/2019
3D InSight™ human liver models helped assess efficacy of praliciguat, a systemic small molecule sGC stimulator, in reducing hallmark symptoms of fatty liver disease.
-
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
7/30/2019
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2019 results and recent business activities.
-
SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
6/25/2019
SmartPharm Therapeutics announced that José Trevejo, MD, PhD, has been appointed Chief Executive Officer.
-
The drug showed a statistically significant and clinically meaningful improvement in overall abdominal symptoms compared to placebo for all primary and secondary endpoints.
-
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
6/13/2019
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the company plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge, Massachusetts. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street
-
Scott Gottlieb to Keynote GNS Healthcare's Precision Medicine Forum
6/3/2019
GNS Healthcare (GNS), a leading precision medicine company, announced today that former FDA Commissioner Scott Gottlieb, M.D. will be keynoting its 2nd annual Precision Medicine and AI Forum on June 14th in Cambridge